BioSpace News Archive

Tetrous, Inc., a regenerative medicine company, today announced that another patent (U.S. Patent Number 11,759,548) specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture has been issued by the United States Patent and Trademark Office.

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will participate in the 2023 Roth Healthcare Opportunities Conference on Thursday, October 12, 2023 in New York.

Ginkgo Bioworks announced that its biosecurity and public health unit, Concentric by Ginkgo, will partner with Northeastern University, which has received a grant from the Centers of Disease Control and Prevention over the next five years to head an innovation center led by a consortium of organizations designed to help the United States to detect and prepare for the next outbreak of infectious disease.

Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to provide an update regarding upcoming data presentations at two international scientific meetings, European Society for Medical Oncology Congress 2023 and Society for Neuro-Oncology Annual Meeting.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023.

Alentis Therapeutics announced the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) is pleased to announce its participation in the Immunoglobulin National Society (“IGNS”) 2023 National Conference, taking place in Denver, Colorado from October 5th to 8th.

Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma versus observation.

Study shows the DecisionDx-Melanoma test identifies more patients who can safely forego SLNB than using current guidelines alone or a clinicopathologic-only nomogram.